thus , in spite of the impressive advances in the safety of commercial factor viii which have recently been implemented , we believe there is a place for single donor cryoprecipitate from plasma exchange donation in the treatment of hemophilia and other bleeding disorders in the 1990 's .
C0015506
factor viii
C0019069
hemophilia